JP2013544809A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544809A5
JP2013544809A5 JP2013537197A JP2013537197A JP2013544809A5 JP 2013544809 A5 JP2013544809 A5 JP 2013544809A5 JP 2013537197 A JP2013537197 A JP 2013537197A JP 2013537197 A JP2013537197 A JP 2013537197A JP 2013544809 A5 JP2013544809 A5 JP 2013544809A5
Authority
JP
Japan
Prior art keywords
composition
composition according
over
period
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544809A (ja
JP5917537B2 (ja
Filing date
Publication date
Priority claimed from GBGB1018650.0A external-priority patent/GB201018650D0/en
Application filed filed Critical
Publication of JP2013544809A publication Critical patent/JP2013544809A/ja
Publication of JP2013544809A5 publication Critical patent/JP2013544809A5/ja
Application granted granted Critical
Publication of JP5917537B2 publication Critical patent/JP5917537B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537197A 2010-11-04 2011-11-04 結腸直腸ガンを治療するためのpeg又はpegブロックコポリマー Expired - Fee Related JP5917537B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1018650.0 2010-11-04
GBGB1018650.0A GB201018650D0 (en) 2010-11-04 2010-11-04 Methods and compositions
US41212810P 2010-11-10 2010-11-10
US61/412,128 2010-11-10
PCT/GB2011/001561 WO2012059725A1 (en) 2010-11-04 2011-11-04 Peg or peg block copolymers for treating colorectal cancer

Publications (3)

Publication Number Publication Date
JP2013544809A JP2013544809A (ja) 2013-12-19
JP2013544809A5 true JP2013544809A5 (enExample) 2014-11-27
JP5917537B2 JP5917537B2 (ja) 2016-05-18

Family

ID=43414365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537197A Expired - Fee Related JP5917537B2 (ja) 2010-11-04 2011-11-04 結腸直腸ガンを治療するためのpeg又はpegブロックコポリマー

Country Status (22)

Country Link
US (2) US20130216493A1 (enExample)
EP (1) EP2635289B1 (enExample)
JP (1) JP5917537B2 (enExample)
KR (1) KR20130109171A (enExample)
CN (1) CN103313719A (enExample)
AR (1) AR083770A1 (enExample)
AU (1) AU2011324996B2 (enExample)
BE (1) BE1019494A3 (enExample)
BR (1) BR112013011012A2 (enExample)
CA (1) CA2816839A1 (enExample)
EA (1) EA201300540A1 (enExample)
ES (1) ES2401269B1 (enExample)
GB (1) GB201018650D0 (enExample)
MX (1) MX349690B (enExample)
MY (1) MY163067A (enExample)
NL (1) NL2007715C2 (enExample)
NZ (1) NZ611145A (enExample)
SG (1) SG189533A1 (enExample)
TW (1) TWI606832B (enExample)
UA (1) UA107998C2 (enExample)
WO (1) WO2012059725A1 (enExample)
ZA (1) ZA201304052B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
KR20170098980A (ko) 2012-09-11 2017-08-30 노어긴 비.브이. Peg 및 아스코르베이트를 포함하는 조성물
AR093153A1 (es) * 2012-10-26 2015-05-20 Northshore Univ Healthsystem Composiciones que comprenden polietilenglicol para la terapia del carcinoma de celulas escamosas de cabeza y cuello
CN103083733A (zh) * 2013-02-19 2013-05-08 华熙福瑞达生物医药有限公司 一种医用体腔器械导入水性润滑剂
WO2020180549A1 (en) * 2019-03-05 2020-09-10 Dow Global Technologies Llc Inducing caspase activity
US12251399B2 (en) 2019-03-05 2025-03-18 Dow Global Technologies Llc Inducing caspase activity
CN113490501B (zh) * 2019-03-05 2024-05-24 陶氏环球技术有限责任公司 用于诱导胱天蛋白酶活性的聚乙二醇衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2784897B1 (fr) 1998-10-27 2002-11-29 Agronomique Inst Nat Rech Utilisation d'un laxatif osmotique non fermente dans le traitement et la prevention des cancers colorectaux
JP5276435B2 (ja) * 2005-05-06 2013-08-28 セイリックス ファーマシューティカルズ, インコーポレイティッド ポリエチレングリコールの結腸の下剤組成物
US8457025B2 (en) * 2009-08-28 2013-06-04 Telefonaktiebolaget L M Ericsson (Publ) Method and network node for selecting a network prefix to be advertised in a communication network

Similar Documents

Publication Publication Date Title
JP2013544809A5 (enExample)
Kienzle-Horn et al. Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation
JP2020528075A5 (enExample)
JP2016523862A5 (enExample)
CN103391775A (zh) 植物大麻素大麻二酚(cbd)与标准抗癫痫药物(saed)组合在治疗癫痫中的用途
US20180116976A1 (en) Methods and compositions for unwanted or abnormal muscle contractions
JP2014500246A5 (enExample)
JP2020055856A (ja) 経口薬剤用補助手段としての組成物
EP2635289B1 (en) Peg or peg block copolymers for treating colorectal cancer
US20180098940A1 (en) Pediatric formulation
UA111480C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ЛІКУВАННЯ СИНДРОМУ ПОДРАЗНЕНОГО КИШЕЧНИКУ, ЯКА ВВОДИТЬСЯ ПЕРОРАЛЬНО, ЩО МІСТИТЬ ТРИМЕБУТИН, СИМЕТИКОН, α-D-ГАЛАКТОЗИДАЗУ, І СПОСІБ ЇЇ ОТРИМАННЯ
RU2725743C2 (ru) Продукт на основе хелата бис-глицината железа и альгиновой кислоты и/или ее водорастворимых солей, его составы и его фармацевтические применения
Contini et al. Features and management of esophageal corrosive lesions in children in Sierra Leone: lessons learned from 175 consecutive patients
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤
JP2007169247A (ja) ショウガ含有経口組成物
JP6549428B2 (ja) 経口組成物
US20210177805A1 (en) Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
JP2017513866A5 (enExample)
JP6641626B2 (ja) 制酸用医薬組成物
BR112014007022B1 (pt) composição farmacêutica, método e uso de uma composição farmacêutica
JP2012097034A5 (enExample)
JP6762007B2 (ja) 変形性関節症予防用組成物、変形性関節症予防用食品組成物、変形性関節症予防用食品添加物及び変形性関節症予防用医薬
JP2003095981A (ja) 医薬組成物
Sharma et al. S1073 Tak-390MR, a Proton Pump Inhibitor (PPI) with a Novel Dual Delayed Release (DDR) Formulation, Is Highly Effective in the Healing of Erosive Esophagitis (EE): Data from Two Randomized Controlled Trials
Metz et al. S1074 Tak-390MR, a Proton Pump Inhibitor with a Novel Dual Delayed Release Formulation, Maintains Healing and Controls Heartburn in GERD Patients with Healed Erosive Esophagitis